CLINICAL_TRIALS
trial_result
· 2017-12-11
Clinical Trial Update: A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) [Phase 2]
Summary
Phase II clinical trial results update for GSK1363089 (XL880) in patients with papillary renal cell carcinoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2017-12-11